-61%

est. 2Y upside i

HealthcareSeries C

Stage: growth. Country: United States of America

Rank

#2429

Sector

AI in Healthcare

Est. Liquidity

~4Y

Data Quality

Data: High

Nabla presents a moderate upside opportunity with higher risk, primarily due to the very recent and significant departure of its co-founder and CEO to lead a partner company.

Last updated: March 10, 2026

Bull (25%)+200%

Nabla successfully navigates the leadership transition, leverages strategic partnerships (like AMI Labs) to accelerate its agentic AI platform, and captures significant market share from legacy documentation methods. Revenue scales to $100M+ by 2028, justifying a $540M+ valuation at a healthy multiple, leading to a strong acquisition or IPO.

Base (30%)+50%

Nabla continues to grow steadily, expanding its customer base and product features, but faces increased competition and regulatory friction. The company maintains its position in ambient AI documentation, reaching ~$50M in revenue by 2028 and achieving a $270M valuation, offering moderate returns for common shareholders.

Bear (45%)-60%

The recent CEO departure creates execution challenges, while dominant EHR incumbents (Epic, Cerner) integrate similar features or acquire competitors, eroding Nabla's market position. Growth stalls, leading to a down round or an exit at a valuation of $72M or less, where the $120M in liquidation preferences would wipe out most, if not all, common stock value.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

67%

Investors hold $120M in liquidation preferences. In an exit at or below the current $180M valuation, common shareholders would receive only $60M ($180M - $120M) or less.

Dilution Risk

high

As a Series C company, Nabla will likely require at least one more significant funding round before an exit, leading to further dilution for existing equity holders.

Secondary Liquidity

limited

Nabla has low market activity with no active buyers or sellers reported, though accredited investors can access shares through platforms like EquityZen and Hiive.

Customer Success — 4 roles

Engineering — 4 roles

Product — 3 roles

Sales — 2 roles

Finance — 1 role

Marketing — 1 role

View all 15 open roles at Nabla →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Nabla's data — designed to show you've done your homework.

  • 1

    “Given the recent news of Alexandre LeBrun's transition to AMI Labs, how does Nabla plan to maintain its strategic vision and execution momentum, particularly in its expansion into agentic AI and continued product development?”

  • 2

    “Nabla has demonstrated impressive revenue growth, multiplying by five in the six months prior to June 2025. What are the key strategies for sustaining this rapid growth trajectory, especially as the company expands its 'agentic AI' capabilities and navigates the competitive landscape with major EHR vendors like Epic and Cerner?”

  • 3

    “With total funding at $120M and a stated valuation of $180M, which implies a significant preference stack, how is Nabla thinking about its path to a liquidity event for common shareholders, and what is the estimated timeline for such an event?”

Community

Valuation Sentiment

Our model estimates -61% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.